• Affinity Maturated T-Cell Receptor (No. T4-1662)

    Scientist: Lea Eisenbach

    Immunotherapy, that is the use of the immune system to treat cancer, is currently a leading candidate in the combat against cancer. Unlike the toxic effects of both chemotherapy and radiation, immunotherapy is considered to have mild side effects due to its ability to differentiate between healthy and cancerous cells. Al ... Read more
  • Agrin – A Novel Protein-Based Therapeutic Agent for Heart Diseases (No. T4-1787)

    Scientist: Eldad Tzahor

    Heart disease is the number one cause of death, surpassing the number of deaths from all cancers combined. Its burden on society and healthcare systems is immense. The inspiring studies from one of the top leaders in the field of cardiac regeneration, Prof. Eldad Tzahor of the Weizmann Institute of Science, into mechanis ... Read more
  • Anti-QSOX1 Antibody for Treating Cancer and Metastasis (No. T4-1642)

    Scientist: Deborah Fass

    A potential target for anticancer drug design.Cancer is the second leading cause of death in the US, accounting for roughly 23% of all deaths (as of 2008), and with estimated cost of care of $157 billion (as of 2010). Despite major advances in the management of cancer, most types of solid tumors remain resistant to conve ... Read more
  • Antibody Combinations in Treating Cancer (No. T4-1518)

    Scientist: Yosef Yarden

    Improved immunotherapy for breast cancer. Monoclonal antibodies (mAbs) to ErbB-2/HER2 growth factor receptor, or to its sibling, the epidermal growth factor receptor (EGFR), prolong survival of cancer patients, especially when combined with cytotoxic therapies. However, low effectiveness of therapeutic mAbs and the evolu ... Read more
  • Bioengineered Microorganisms that can "Eat" (Fix) CO2 (No. T4-1736)

    Scientist: Ron Milo

    Biomass production by plants and other photosynthetic organisms involves carbon fixation, the process of incorporating inorganic carbon dioxide into organic compounds. Currently carbon fixation by plants and other photosynthetic organisms is the limiting factor in biomass production. Improvement in the metabolic pathway ... Read more
  • Biological Treatment for Pancreatic Cancer (MMP7 mAb) (No. T4-1640)

    Scientist: Irit Sagi

    The innovative concept leading to this high selectivity is immunization with both a synthetic metal-protein mimicry molecule, previously developed by the present inventors, followed by the metalloenzyme itself (e.g. MMP-7). The resulting antibody exhibits exceptional degree of specificity towards MMP-7 over other MMPs.Th ... Read more
  • CD84 - a Novel Regulator of B-CLL Survival (No. T4-1441)

    Scientist: Idit Shachar

    Chronic lymphocytic leukemia (CLL), a malignant disease characterized by the accumulation of B lymphocytes in the blood, lymphoid organs, and bone marrow, is the second most common type of leukemia in adults, accounting for about 7,000 new cases of leukemia each year. Presently, there is no cure for CLL, and the overall ... Read more
  • Cholesterol Antibodies (No. T4-1267)

    Scientist: Lia Addadi

    Description: Monoclonal antibodies specific for cholesterol/ceramide-rich domains (clones 405F, 14F, 499F) and cholesterol micro-domains (clones 36A1, 5881) in cell membranes. Originally raised against an artificial monolayer of lipid mixtures in, and were shown to specifically label the above domains in different cell ... Read more
  • Disrupting or Preventing Formation of Biofilm by Enzyme Inhibitors (No. T4-1893)

    Scientist: Ilana Kolodkin-Gal

    Biofilm is a complex colony of bacteria, which are attached together by extracellular polymeric substance. This setting provides the bacteria protection against environmental factors, improves their surface attachment, and plays a major role in resistance to treatment. Therefore, biofilms are difficult to eradicate, much ... Read more
  • ERBB2 as a Novel Target to Treat Heart Failure by Inducing Cardiomyocyte Proliferation (No. T4-1752)

    Scientist: Eldad Tzahor

    Existing treatments fail to compensate the irreversible loss of functional cardiomyocytes (CM), thus presenting a major medical unmet need. Inducing native CM replacement is one approach being tested as regenerative treatment, with the advantage of a more straightforward methodology over cell transplantation approaches. ... Read more


Subscribe to Pharmaceuticals